Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,402 | 1,507 | 1,658 | 1,754 | 1,722 |
| Receivables | N/A | N/A | 171 | N/A | N/A |
| TOTAL | $1,469 | $1,611 | $1,916 | $1,883 | $1,895 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 204,888 | 203,944 | 202,916 | 202,145 | 201,332 |
| TOTAL | $204,888 | $203,944 | $202,916 | $202,145 | $201,332 |
| Total Assets | $206,357 | $205,555 | $204,832 | $204,028 | $203,227 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 746 | 342 | 429 | 350 | 127 |
| Other current liabilities | N/A | N/A | 9 | 9 | 9 |
| TOTAL | $327 | $387 | $438 | $359 | $135 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 200,587 | 200,168 | 199,392 | 198,669 | 198,091 |
| TOTAL | $200,600 | $200,168 | $199,394 | $198,669 | $198,091 |
| Total Liabilities | $201,357 | $200,555 | $199,832 | $199,028 | $198,227 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 7 | 7 | 7 | 7 | 7 |
| Common Shares | 1 | 1 | 1 | 1 | 1 |
| Retained earnings | 3,286 | 2,867 | 2,091 | 1,368 | 790 |
| TOTAL | $5,000 | $5,000 | $5,000 | $5,000 | $5,000 |
| Total Liabilities And Equity | $206,357 | $205,555 | $204,832 | $204,028 | $203,227 |